Promotion of myofibroblast apoptosis is a potential therapeutic strategy for pulmonary fibrosis. This study investigated the antifibrotic effect of astaxanthin on the promotion of myofibroblast apoptosis based on dynamin-related protein-1 (Drp1)-mediated mitochondrial fission in vivo and in vitro. Results showed that astaxanthin can inhibit lung parenchymal distortion and collagen deposition, as well as promote myofibroblast apoptosis. Astaxanthin demonstrated pro-apoptotic function in myofibroblasts by contributing to mitochondrial fission, thereby leading to apoptosis by increasing the Drp1 expression and enhancing Drp1 translocation into the mitochondria. Two specific siRNAs were used to demonstrate that Drp1 is necessary to promote astaxanthin-induced mitochondrial fission and apoptosis in myofibroblasts. Drp1-associated genes, such as Bcl-2-associated X protein, cytochrome c, tumour suppressor gene p53 and p53-up-regulated modulator of apoptosis, were highly upregulated in the astaxanthin group compared with those in the sham group. This study revealed that astaxanthin can prevent pulmonary fibrosis by promoting myofibroblast apoptosis through a Drp1-dependent molecular pathway. Furthermore, astaxanthin provides a potential therapeutic value in pulmonary fibrosis treatment.
Introduction
Myofibroblasts contribute to the pathogenesis in pulmonary fibrosis because of their increased production of extracellular matrix (ECM) and fibrogenic mediators, resulting in the loss of alveolar function [1] . The presence, differentiation and persistence of myofibroblasts determine the degree of fibrogenesis [2] . Given that excessive myofibroblasts are eliminated by apoptosis in the normal wound repair process [3, 4] , the induction of myofibroblast apoptosis is a potential therapeutic strategy for both the prevention and treatment of pulmonary fibrosis.
Mitochondria are highly dynamic organelles that undergo constant fusion and fission; the resulting morphological changes in the mitochondrial network are necessary for the mitochondrial functions in living cells to adapt to various conditions [5, 6] . This phenomenon highlights the importance of homoeostasis between fission and fusion. Mounting experiments have shown that abnormal mitochondrial fission occurs during pathophysiological events, such as neurodegeneration, cellular aging and apoptosis [7, 8] . Dynamin-related protein-1 (Drp1), also called Dnm1 in yeast, belongs to the dynamin GTPase superfamily, which mediates the formation of a helical ring around the outer mitochondrial membrane to segment the mitochondria into discrete compartments [9, 10] . Previous research revealed that the inhibition of Drp1 by overexpression of Drp1K38A, a Drp1-dominant-negative mutant, reduced the mitochondrial fragmentation; extensively fragmented mitochondrial morphology was also associated with Drp1 translocation to the mitochondria [11, 12] . Therefore, regulation of Drp1-dependent mitochondrial fission is crucial for the development of drugs for intervening myofibroblastic apoptosis.
Astaxanthin, a non-provitamin A carotenoid, functions as a principal pigment in crustaceans, salmonoids and other organisms. Astaxanthin also demonstrates great applications in food, feed, nutraceutical and pharmaceutical industries [13, 14] . The European Commission considers natural astaxanthin as a functional food agent for preventing or reducing various disorders in humans and animals, such as neurodegeneration, cardiovascular diseases, diabetes and cancer [15, 16] . Our previous work revealed the preventive function of astaxanthin in pulmonary fibrosis, as well as its effects on the transdifferentiation, proliferation and apoptosis of myofibroblasts [17] ; however, we did not investigate the mechanism of astaxanthin in promoting myofibroblast apoptosis. Therefore, our present study investigated the mechanism of astaxanthin in promoting myofibroblast apoptosis through the signalling pathway of Drp1-mediated mitochondrial fission.
Materials and methods

Human tissue samples
Patients were diagnosed with pulmonary fibrosis through combined clinical, radiological and pathological findings according to the American Thoracic Society/European Respiratory Society consensus criteria [18] . Biopsy samples from six patients were routinely placed in formaldehyde or glutaraldehyde for surgical and pathological evaluation. Control samples were obtained from six patients with primary lung carcinoma who underwent thoracic surgery. The protocol was approved by the local ethics committee, and written informed consent with accompanying images was obtained from the patients for publication of this report.
Animal model
A pulmonary fibrosis model was established by the instillation of the chemotherapeutic agent bleomycin. Briefly, Sprague-Dawley (SD) rats weighing 200 g were purchased from the Yantai Green Leaf Experimental Animal Center and randomly divided into three groups (with 15 rats for each group): sham group, bleomycin group and bleomycin + astaxanthin group. Pulmonary fibrosis in rats was induced by a single intratracheal instillation of 5 mg/kg bleomycin in 0.3 ml of saline, whereas the rats in the sham group received equal volume of saline. The rats in the bleomycin + astaxanthin group were administered daily with 2 mg/ kg astaxanthin beginning on the 14th day after bleomycin injury (i.e. post-inflammatory fibrotic phase) for 7 or 14 days [19] , whereas the rats in other groups were given water. Rats were killed on the 21st or 28th day. Portions of tissue samples were immediately frozen in liquid nitrogen for quantitative real-time PCR (qRT-PCR) and Western blot analysis, fixed in 4% formaldehyde for immunohistochemistry, and fixed in 2.5% glutaraldehyde for ultrastructural observation. All the rats in our experiments received the guiding principles of care in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Cell model
Human lung fibroblast MRC-5 and lung adenocarcinoma 549 (A549) cell lines were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Both cell lines were maintained at 37°C in DMEM supplemented with 10% newborn calf serum under a humidified atmosphere of 5% CO 2 . The cells were divided into four groups: control group, transforming growth factor-beta 1 (TGF-b1) group, astaxanthin group and TGF-b1+ astaxanthin group (n = 6 per group). The cells were pre-treated with 5 ng/ml TGF-b1 (Invitrogen, Carlsbad, CA, USA) for 72 hrs for transdifferentiation of myofibroblasts then co-treated with or without astaxanthin (24 and 18 lg/ml for A549 and MRC-5 cells, respectively) for another 48 hrs.
Histopathological examination
Lung tissues of all the groups were fixed with 4% para-formaldehyde and later embedded in paraffin. Transverse sections of 4 lm-thick slices were stained with hematoxylin and eosin (Sigma-Aldrich, St. Louis, MO, USA) and Masson's trichrome (Maxin Company, Fuzhou, China). The percentage of lung fibrosis was evaluated by counting the number of pixels in the digital images corresponding to the stained collagen areas by using Adobe Photoshop CS3, as previously described [20, 21] .
Transmission electron microscopy observation
Cell and tissue samples were initially fixed in fresh 2.5% glutaraldehyde for at least 4 hrs at 4°C, post-fixed in 1% osmium tetroxide for 1.5 hrs, dehydrated in a gradient ethanol series and infiltrated with Epon812. The samples were then embedded and cured at 37°C for 12 hrs, 45°C for 12 hrs and 60°C for 24 hrs. Ultrathin sections were cut using ultracut E ultramicrotome (Leica, Wetzlar, Germany) and stained with uranyl acetate and lead citrate before observation under the JEM-1400 transmission electron microscope (TEM; JEOL Ltd., Tokyo, Japan).
Immunofluorescence analysis
The tissue sections and cells cultured on coverslips were fixed in 4% para-formaldehyde, rinsed with PBS, incubated in 0.5% Triton X-100 for 20 min. and blocked nonspecific antigens with 10% serum. Samples were then incubated overnight at 4°C with primary antibodies including anti-a-smooth muscle actin (a-SMA), anti-Bcl-2-associated X protein (Bax), anti-Drp1, anti-p53-up-regulated modulator of apoptosis (PUMA), anti-surfactant-associated protein (SP-C) and anti-Snail (Santa Cruz Biotechnology, Watsonville, CA, USA). Subsequently, treated samples were rinsed with PBS and then incubated with secondary antibodies labelled with FITC (fluorescein isothiocyanate) and Cy3 for 60 min. in six visual fields that were randomly selected from each slide by two blinded observers.
In situ terminal deoxynucleotidyl transferase dUTP nick end labelling
Terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay was performed in the paraffin sections of the lung tissues by using the Fluorometric TUNEL System from KeyGen Biotech in accordance with the manufacturer's instructions. Sections were counterstained with Hoechst 33258 dye for nuclear staining and photographed using a confocal laser fluorescence microscope (Leica). TUNEL-positive cells were counted in six visual fields that were randomly selected from each slide by two blinded observers.
Flow cytometry measurement
Suspended and adherent cells were collected and washed with cold PBS. Up to 500 ll of binding buffer was added to resuspend the cells. Annexin V-FIFC (5 ll) and propidium iodide staining solution (5 ll; Beyotime, Jiangsu, China) were added for 20 min. and incubated in the dark. The apoptotic rate was measured by flow cytometry (Beckman, Fullerton, CA, USA).
Mitochondrial staining
Cells were plated onto coverslips coated with 0.01% poly-L-lysine. Upon treatment following the protocol described previously, the cells were stained for 35 min. with 200 nM MitoTracker Red CMXRos (Molecular Probes; Invitrogen, Carlsbad, CA, USA), and immunofluorescence staining was performed. Samples were visualized using a laser scanning confocal microscope (Leica).
Live cell imaging
Cells were plated onto 35 mm glass-bottom dishes (Corning, Corning, NY, USA) and allowed to adhere for 24 hrs. The cells were then treated with 5 ng/ml TGF-b1 (Invitrogen) for 72 hrs. After staining with 100 nM MitoTracker Red CMXRos (Molecular Probes) for 35 min., the cells were administered with or without astaxanthin, and cell imaging was performed. The cells were observed on a live cell imaging system (DV ELITE; API, Fairfield, CT, USA) with a temperature-controlled incubation chamber maintained at 37°C. MitoTracker Red CMXRos was excited with a Chameleon Multiphoton laser emitting 579 nm laser pulses. Emission was collected at 599 nm.
qRT-PCR analysis
Total RNA was isolated from lung tissues and cells by using TRIzol reagent (Invitrogen) then twofold serially diluted in nuclease-free water. Up to 2 lg of RNA was used for first-strand cDNA synthesis. qRT-PCR analysis was performed with the Rotor-Gene 3000 Real-time PCR system with the following reaction profiles: pre-denaturation at 95°C for 30 sec. and PCR amplification for 40 cycles with 95°C for 15 sec. and 60°C for 25 sec. PCR was followed by a melt curve analysis to determine the reaction specificity. The relative gene expression was calculated using standard DDCt methods by Rotor-Gene 6 Software. GAPDH RNA was quantified as a control to normalize differences in total RNA levels. The following primers were used to quantify the Drp1 levels:
Transfection of siRNA
Two siRNA sequences targeting human Drp1 gene were synthesized by Guangzhou RiboBio Co., Ltd, Development zone, Scientific town, GuangZhou, China. For transfection, cells were placed on six-well plates.
Transfections were performed with Lipo2000 for 24 hrs as directed by the manufacturer (Invitrogen). The final siRNA concentration was 25 nM. The transfected samples were treated as described above.
Western blot analysis
Proteins of lung tissues and cells were extracted, and protein concentration was quantified using the bicinchoninic acid protein assay kit (Beyotime). Protein samples were separated by 15% SDS-PAGE for 2 hrs, transferred onto a polyvinylidene difluoride membrane and blocked in 5% non-fat milk for 2 hrs. Blots were incubated overnight with the specific primary antibodies against a-SMA, Snail, Bax, Drp1, cytochrome c, p53 and PUMA (Santa Cruz Biotechnology) at 4°C, followed by the addition of species-specific horseradish peroxidase-conjugated secondary antibodies with IgG, and further incubation for 1 hr at room temperature. Immunoreactive bands were visualized using the ECL-assay kit (Beyotime). For detection of mitochondrial Drp1, mitochondrial protein was isolated from the lungs of rats by using a mitochondria isolation kit (Beyotime). The band's density was analysed and quantified using a ChemiScope series and ChemiAnalysis software.
Statistical analysis
All data were presented as mean AE SD. Unpaired Student's t-test was used for experiments comparing two groups, whereas one-way ANOVA with Student-Newman-Keuls post hoc test was applied for experiments comparing three or more groups. All analyses were performed with SPSS statistical package (version 11.0 for Windows; SPSS Inc., Chicago, IL, USA). A P < 0.05 was considered statistically significant.
Results
Emergence of myofibroblasts in pulmonary fibrosis
To examine the presence of myofibroblasts in human lung fibrosis, macroscopic and microscopic changes of autopsy samples from patients with pulmonary fibrosis were determined using TEM and laser scanning confocal microscope. The TEM results showed that myofibroblasts and excessive ECM existed in human fibrotic lung tissues (middle panel). Moreover, AECs-II contained bundles of filaments in its cytoplasm (right panel; Fig. 1A ). Simultaneously, SP-C + (the AECs-II specific marker) and a-SMA + (the myofibroblasts specific marker) dual-positive cells were significantly present in the human fibrotic lung tissues detected by immunofluorescence staining (Fig. 1B and C) . The levels of Snail, a well-established master transcription regulator of epithelial-mesenchymal transition during the development of pulmonary fibrosis, also increased in autopsy samples from patients with pulmonary fibrosis (Fig. 1D and E) . These findings confirmed that AECs-II can transdifferentiate into myofibroblasts in human pulmonary fibrosis. We also tested the emergence of myofibroblasts in bleomycin-induced rat and TGF-b1-stimulated cell fibrotic models by using the same methods. As shown in Figure 2A , many myofibroblasts (middle panel) and AECs-II displaying mesenchymal phenotypes (right panel) were detected in rat fibrotic lung tissues. Moreover, the number of cells co-expressing SP-C and a-SMA and levels of Snail increased significantly in rat fibrotic lung tissues (Fig. 2B-D) . As the transition of myofibroblasts from their precursors was driven by TGF-b1, we stimulated MRC-5 and A549 cells with 5 ng/ml TGF-b1 for 72 hrs. The results also showed that a-SMA and Snail were significantly up-regulated in the TGF-b1 group (Fig. 2E  and F) . Thus, the emergence of myofibroblasts, which can result from AECs-II in vivo and in vitro, was similar to that in actual patients. This finding indicated that our pulmonary fibrosis model was significant for this study. 
Astaxanthin prevented pulmonary fibrosis
To detect the therapeutic effect of astaxanthin on lung fibrosis, we administered bleomycin-injured rats with or without astaxanthin in their post-inflammatory fibrotic phase. Bleomycin-induced fibrotic rats displayed increased lung parenchymal distortion, showing thicker alveolar membrane and severe oedema (Fig. 3A) . However, astaxanthin treatment evidently ameliorated these injuries. Astaxanthin markedly attenuated collagen deposition as shown by Masson's trichrome staining (Fig. 3B ). An evident decrease in hydroxyproline was observed upon astaxanthin treatment for 7 and 14 days (Fig. 3C) . Myofibroblast is the most contributing cell for collagen. In this study, we assessed whether astaxanthin can reduce the number of myofibroblasts. The results showed that a-SMA-positive cells were even less in the lung tissues of astaxanthin-treated rats (Fig. 4A) . Moreover, astaxanthin treatment for 7 and 14 days significantly decreased the a-SMA protein level, which was consistent with the scoring of fibrosis ( Fig. 4B and C) . These results indicated that astaxanthin ameliorated lung fibrosis partly because of its ability to reduce myofibroblasts in lung tissues.
Astaxanthin promoted myofibroblast apoptosis
To further explore the effect of astaxanthin on myofibroblasts, we compared the myofibroblast apoptosis between the astaxanthin-treated and -untreated lung tissues after bleomycin instillation. Representative immunofluorescence images clearly showed that the number of TUNEL-positive cells significantly increased in the lung tissues of the astaxanthin-treated rats for 7 and 14 days compared with the astaxanthin-untreated rats after bleomycin exposure. treatment significantly promoted myofibroblast apoptosis ( Fig. 5A  and B) . Double immunofluorescence staining also revealed Bax overexpression induced by astaxanthin, which primarily occurred in myofibroblasts (Fig. 6A) . Western blot confirmed that Bax expression was highly up-regulated in astaxanthin-treated rats (Fig. 6B) .
Flow cytometry analysis showed that the apoptotic rate of cells increased from 8.58% representing the basal levels of apoptosis to 39.88% in TGF-b1-activated A549 cells and 11.55% representing the basal levels of apoptosis to 43.03% in TGF-b1-activated MRC-5 cells treated with astaxanthin for 48 hrs (Fig. 7A) . Western blot analysis also showed that astaxanthin increased Bax expression in TGF-b1-mediated A549 and MRC-5 cells (Fig. 7B) . Moreover, double immunofluorescence staining revealed that astaxanthin treatment significantly induced the Bax overexpression in myofibroblasts, although fibroblasts were insensitive to the apoptosis-inducing effects of astaxanthin (Fig. 7C) .
The in vitro and in vivo results strongly supported that astaxanthin can promote myofibroblast apoptosis.
Astaxanthin-induced mitochondrial fission
Increasing evidence has shown that mitochondrial fission plays a critical role in initiating cell apoptosis [22, 23] . We explored the regulatory effect of astaxanthin on mitochondrial fission. Confocal microscope images showed that the mitochondria of control myofibroblasts existed in a normal elongated tubular structure. However, astaxanthin caused nearly a fourfold increase in the number of cells displaying punctuated mitochondrial structures in TGF-b1-activated A549 and MRC-5 cells (Fig. 8A) . To further confirm this morphological change in the mitochondria, cells were tracked real-time by using the live cell imaging system immediately after astaxanthin treatment. The results showed that the tubular network of the mitochondria began to transform into fragmented independent organelles within 6 hrs after treatment (Fig. 8B) . Ultrastructural findings also showed that astaxanthin induced the mitochondria to transform from a long and filamentous structure into a round and short-shaped formation, which indicated mitochondrial fission. Quantitative results showed that astaxanthin significantly decreased the ratio of fused mitochondria/fissional mitochondria in the TGF-b1-activated A549 and MRC-5 cells (Fig. 8C) . These data indicated that astaxanthin can modulate mitochondrial fission.
Drp1 is necessary for astaxanthin-induced mitochondrial fission and apoptosis
Dynamin-related protein-1 is considered the key player in mitochondrial fission. We investigated whether the apoptotic response of myofibroblasts to astaxanthin was mediated by Drp1-dependent mitochondrial fission. Dynamin-related protein-1-specific siRNA was used to knockdown Drp1 in both TGF-b1-activated-A549 and MRC-5 cells.
The efficiency of siRNA was measured by RT-PCR and Western blot analysis before and after transfection (Fig. 9A) . Considering the different efficiencies of two Drp1 siRNAs, activated-A549 cells were transfected with siR-Drp1 (1), whereas activated-MRC-5 cells were transfected with siR-Drp1 (2) for further studies. Two Drp1 siRNAs significantly reduced the number of cells undergoing mitochondrial fission caused by astaxanthin (Fig. 9B) . The siR-Drp1 (1) caused a 3.6-fold decrease in astaxanthin-induced cell apoptosis in activated-A549. The siR-Drp1 (2) caused nearly the same degree of reduction in astaxanthin-induced cell apoptosis in the activated-MRC-5 cells (Fig. 9C) . Western blot results showed that astaxanthin increased the level of cytoplasmic cytochrome c in the activated-A549 and MRC-5 cells, whereas the cytochrome c release induced by astaxanthin was largely abolished by Drp1 siRNA (Fig. 9D) . The results confirmed that astaxanthin promoted myofibroblast apoptosis mainly by activating Drp1-dependent mitochondrial fission pathway.
Astaxanthin promoted Drp1 expression and translocation
To understand the modulation of astaxanthin on Drp1, we detected the changes in expression and translocation of Drp1 in myofibroblasts with or without astaxanthin treatment. The results showed that the mRNA levels of Drp1 were significantly increased by 4.3-and 17.3-fold, respectively, in the lung tissues treated with astaxanthin for 7 and 14 days as compared with the bleomycin group (Fig. 10A) . The protein levels also increased (Fig. 10B) . Astaxanthin treatment significantly increased the Drp1 expression in mRNA ( Fig. 10C and E ) and the protein levels ( Fig. 10D and F) in the TGF-b1-mediated A549 and MRC-5 cells, which further confirmed the in vivo findings. Double immunofluorescence staining results showed that astaxanthin significantly promoted the accumulation of Drp1 in the mitochondria of the TGF-b1-activated A549 and MRC-5 cells (Fig. 10G) . Moreover, in vivo immunoblot analysis revealed that the mitochondrial Drp1 protein levels were significantly increased in the lung tissues treated with astaxanthin for 7 and 14 days compared with the bleomycin group (Fig. 10H) . These results suggested that astaxanthin can promote the translocation of Drp1 from cytosol to mitochondria in vivo and in vitro.
We also explored the Drp1-associated genes during mitochondrial fission. The results revealed that astaxanthin up-regulated the levels of p53, which yielded and elevated Drp1 levels in vivo (Fig. 11A) . Consistent with the change in p53, the level of PUMA also increased and correlated with the accumulation of Drp1 in the mitochondria induced by astaxanthin (Fig. 11B) .
Discussion
Myofibroblasts are clinically and biologically important pathological features of pulmonary fibrosis, and their numbers on surgical lung biopsy directly correlate with progressive physiological deterioration and shortened survival [24, 25] . Although resident fibroblasts activate into myofibroblasts in response to injury, their origin in lung fibrosis remains controversial [26] [27] [28] . Willis et al. [29] showed that AECs gradually lose their epithelial cell markers and polarity during human lung fibrogenesis. Simultaneously, these cells express mesenchymal markers and acquire single-cell motility. Kim et al. [30] also demonstrated the existence of epithelial-mesenchymal transition in lung biopsy samples from fibrotic patients. However, Yamada et al. [31] obtained conflicting results and did not detect double-positive cells for E-cadherin or surfactant-associated protein A, as well as a-SMA or vimentin, in lung tissues from patients with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia. Furthermore, Rock et al. excluded pericytes and two epithelial cell populations as the origin of myofibroblasts [32] . Our current work revealed that myofibroblasts, which can originate from AECs-II were detected in patients with pulmonary fibrosis. This phenomenon also existed in the lung tissues from bleomycin-induced lung fibrotic rats and cultured A549 and MRC-5 cells activated by TGF-b1. Thus, the use of these models is significant to further investigate the action of astaxanthin against pulmonary fibrosis by promoting myofibroblast apoptosis, which is based on Drp1-mediated mitochondrial fission. A more recent study found that pulmonary fibrosis exhibited several cancer-like pathogenic features; thus, pulmonary fibrosis is considered to be a neoproliferative disorder of the lung [33] . Similar to cancer cells, myofibroblasts show epigenetic and genetic abnormalities, as well as functional features such as uncontrolled proliferation, resistance to apoptosis and high migration rates [34] . Thus, promotion of myofibroblast apoptosis is becoming a potential therapeutic strategy for fibrotic diseases [19] . The current results showed that astaxanthin strongly improved lung parenchymal injury, reduced collagen deposition and promoted myofibroblast apoptosis through Drp1-mediated mitochondrial fission signalling pathway.
Several studies reported that astaxanthin effectively co-localized with mitochondria in many types of cells and tissues, such as leucocytes, mesangial cells, blastocysts, liver and muscles, implicating a role of astaxanthin in the mitochondria [35] . Studies have shown that astaxanthin can impair the mitochondrial function and induce apoptosis in certain cancer cells through the mitochondrion-dependent pathways [36] [37] [38] . Mitochondrial fission is important to maintain cellular function and initiate intrinsic apoptosis [39, 40] . Few functional food agents were identified to influence mitochondrial morphology leading to apoptosis. The present results showed that astaxanthin strongly promoted mitochondrial fission in myofibroblasts.
Dynamin-related protein-1, a conserved evolution protein, is one of the proteins proposed to participate in fission process [41] . Dynamin-related protein-1 is a cytosolic protein with an N-terminal GTPase domain, a dynamin-like middle domain and a C-terminal GTPase effector domain, and considered as the principal activator of mitochondrial fission in a GTP-dependent manner [42, 43] . Mitochondrial fission may be controlled by regulating the expression and altering the activity of fission proteins, whereas Drp1 activity is often altered by mitochondrial recruitment, post-translational modification and conversion into its oligomer state [44] . Its localization to the mitochondrial surface is important for mitochondrial fission [45] . Zhang et al. [46] reported that overexpression of Drp1 was critical for cytoplasmic irradiation induced mitochondrial fission. Consistent with the previous work, our observation revealed that astaxanthin significantly increased Drp1 level and promoted the recruitment of Drp1 into mitochondria. Moreover, Drp1 deficiency by RNA interference and the use of a dominant-negative mutant protein (K38A) and a chemical inhibitor (mdivi-1) are known to delay the release of cytochrome c and subsequent apoptosis on challenge with apoptotic stimuli in various types of cultured mammalian cells [47, 48] . Din et al. [49] reported that Drp1 persistent accumulation in the mitochondria was associated with cell apoptosis or death. In agreement, Drp1 siRNA verified that Drp1 was directly essential for astaxanthin-induced mitochondrial fission leading to myofibroblast apoptosis.
Wang et al. [50] suggested that p53 presented direct implication for the regulation of mitochondrial fission through Drp1. Li et al. [51] also reported that Drp1 was transcriptionally up-regulated by p53, which conveyed the apoptotic signal of p53 by triggering mitochondrial fission in cardiomyocytes. The current data demonstrated that the regulation of astaxanthin on the Drp1 level was highly correlated with that of p53. PUMA is exclusively located in the mitochondria, which can facilitate the irreversible immobilization of Drp1 to the mitochondrial outer membrane through protein-protein interactions which form multimeric complexes [52, 53] . In agreement, the present data showed that Drp1 was co-localized with PUMA during astaxanthin-induced mitochondrial fission, leading to myofibroblast apoptosis.
In summary, we clarified the effects of pharmacological inhibition of astaxanthin on pulmonary fibrosis and found that this action required induction of myofibroblast apoptosis by activating the Drp1-mediated mitochondrial fission pathway. This finding suggested that Drp1 exhibits potential benefits for developing astaxanthin as a novel drug for pulmonary fibrosis.
